Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 1/20 | 0.35 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.34 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.30 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.30 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.30 |
| ▸ | ITGAV | P06756 | 1/20 | 0.30 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.30 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.30 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.30 |
| ▸ | ITGAL | P20701 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16854473 | 0.84 | BIRC2 (0.38) | BIRC2PLA2G10PLA2G5SIGMAR1MAPT | |
| SCHEMBL16826797 | 0.84 | BIRC2 (0.38) | BIRC2PLA2G10PLA2G5SIGMAR1MAPT | |
| SCHEMBL8815561 | 0.82 | BIRC2 (0.40) | BIRC2ITGB3ITGB2ITGB1ITGAV | |
| SCHEMBL2906920 | 0.82 | BIRC2 (0.37) | BIRC2PLA2G10PLA2G5SIGMAR1MAPT | |
| SCHEMBL24296905 | 0.81 | BIRC2 (0.36) | BIRC2SIGMAR1MAPT | |
| SCHEMBL991445 | 0.80 | PLA2G10 (0.34) | PLA2G10PLA2G5ITGB3ITGB2ITGB1 | |
| SCHEMBL17153062 | 0.79 | BIRC2 (0.55) | BIRC2PLA2G10PLA2G5 | |
| SCHEMBL6100284 | 0.79 | BIRC2 (0.41) | BIRC2ITGB3ITGB2ITGB1ITGAV | |
| SCHEMBL15894887 | 0.79 | BIRC2 (0.38) | BIRC2ITGB3ITGB2ITGB1ITGAV | |
| SCHEMBL4213475 | 0.76 | SIGMAR1 (0.44) | PLA2G10PLA2G5SIGMAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332149-B1 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-02-19 | — | — | US | disclosed |
| US-7321045-B2 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| US-7018611-B2 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-03-28 | — | — | US | disclosed |
| US-20050154185-A1 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2005-07-14 | — | — | US | disclosed |
| US-6838074-B2 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-04 | — | — | US | disclosed |
| US-20040208823-A1 | SIMULTANEOUS IMAGING OF CARDIAC PERFUSION AND A VITRONECTIN RECEPTOR TARGETED IMAGING AGENT | LANTHEUS MEDICAL IMAGING, INC. | 2004-10-21 | — | — | US | disclosed |
| US-6794518-B1 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-21 | — | — | US | disclosed |
| US-6743412-B2 | ADMINISTERING TO TREAT RHEUMATOID ARTHRITIS, CANCER, RESTENOSIS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-6689337-B2 | TARGETING MOIETY OF A QUINOLONE NONPEPTIDE BOUND TO A CHELATOR AND ALSO BINDS TO A RECEPTOR THAT IS UPREGULATED DURING ANGIOGENESIS; IMAGING COMPOUNDS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-02-10 | — | — | US | disclosed |
| US-6683163-B2 | MONITORING ANGIOGENESIS FACTOR | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-01-27 | — | — | US | disclosed |
| US-20030124120-A1 | Quinolone vitronectin receptor antagonist pharmaceuticals | HARRIS THOMAS D (US) | 2003-07-03 | — | — | US | disclosed |
| US-20030113336-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS HOLDINGS, INC. | 2003-06-19 | — | — | US | disclosed |
| US-20030103898-A1 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | LANTHEUS MEDICAL IMAGING, INC. | 2003-06-05 | — | — | US | disclosed |
| US-6524553-B2 | A compound, comprising: a targeting moiety and a chelator, wherein the targeting moiety is bound to the chelator, is a qinolone nonpeptide, and binds to a receptor that is upregulated during angiogenesis | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-02-25 | — | — | US | disclosed |
| US-6511649-B1 | Chemotherapeutic, a radiosensitizer agent, and a targeting moiety bound to chelator and is a quinolone nonpeptide that binds to a receptor; therapeutically effective radioisotope or diagnostically effective imageable moiety; cancer | LANTHEUS MI REAL ESTATE, LLC | 2003-01-28 | — | — | US | disclosed |
| US-6511648-B2 | Diagnosis, therapy cancer | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-28 | — | — | US | disclosed |
| US-20020182147-A1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | LANTHEUS MI REAL ESTATE, LLC | 2002-12-05 | — | — | US | disclosed |
| US-20020061909-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MI REAL ESTATE, LLC | 2002-05-23 | — | — | US | disclosed |
| US-20020015680-A1 | QUINOLONE VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | CITIZENS BANK, N.A. | 2002-02-07 | — | — | US | disclosed |
| US-6322770-B1 | FOR DIAGNOSIS AND TREATMENT OF CANCER, IMAGING TUMORS, MONITORING THERAPEUTIC ANGIOGENESIS TREATMENT AND DESTRUCTION OF NEW ANGIOGENIC VASCULATURE; COMPRISED OF TARGETING MOIETY THAT BINDS TO RECEPTOR AND RADIOISOTOPE | DUPONT PHARMACEUTICALS COMPANY | 2001-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030124120-A1 | Quinolone vitronectin receptor antagonist pharmaceuticals | ADGRF1, QRFPR, ADGRE5 | BIRC2 3202/4885PLA2G10 4304/4885PLA2G5 3205/4885 |
| US-20030103898-A1 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | TNNI3, ASGR1, TNNT2 | BIRC2 1412/4885PLA2G10 2384/4885PLA2G5 1351/4885 |
| US-20020015680-A1 | QUINOLONE VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | ADGRF1, QRFPR, ADGRE5 | BIRC2 3202/4885PLA2G10 4304/4885PLA2G5 3205/4885 |
| US-20040208823-A1 | SIMULTANEOUS IMAGING OF CARDIAC PERFUSION AND A VITRONECTIN RECEPTOR TARGETED IMAGING AGENT | TNNI3, ASGR1, TNNT2 | BIRC2 1412/4885PLA2G10 2384/4885PLA2G5 1351/4885 |
| US-20030113336-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | BIRC2 1709/4885PLA2G10 3341/4885PLA2G5 1789/4885 |
| US-20050154185-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | BIRC2 1080/4885PLA2G10 2804/4885PLA2G5 1595/4885 |
| US-20020061909-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | BIRC2 1696/4885PLA2G10 3424/4885PLA2G5 1757/4885 |
| US-20020182147-A1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | ADGRF1, RXFP1, VCAM1 | BIRC2 1696/4885PLA2G10 3424/4885PLA2G5 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.